Hawaii Medicaid spending on GLP-1 drugs

How much did Hawaii Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $33.9 million for GLP-1 drugs paid through Hawaii Medicaid in 2025, across at least 30,478 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 49 rows of 144, so these figures are floors.

Pharmacies were reimbursed at least $7.4 million for GLP-1 drugs paid through Hawaii Medicaid in 2026 (quarter 1 only, as posted so far), across at least 6,109 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 9 rows of 35, so these figures are floors.

By year and ingredient

2020at least $4,054,272No data$3,414,414at least $3,004,657at least $244,438$87,967at least $7,912at least $10,813,659
2021at least $6,217,618No dataat least $2,480,067at least $4,982,213at least $311,518$87,150Suppressedat least $14,078,566
2022at least $9,384,355at least $31,031at least $1,269,443at least $6,397,099$425,678$102,333Suppressedat least $17,609,939
2023at least $16,265,280at least $746,179at least $912,655at least $8,380,215at least $364,618$147,809Suppressedat least $26,816,757
2024at least $25,739,985at least $1,894,628at least $588,828at least $6,778,633$183,748$93,701Suppressedat least $35,279,522
2025at least $26,856,026at least $3,609,007at least $374,024at least $2,991,673at least $14,079at least $27,427No dataat least $33,872,236
2026 (Q1)at least $5,933,694at least $1,154,437at least $52,773$248,362SuppressedSuppressedNo dataat least $7,389,266

By product, 2025

Ozempicat least $24,066,856at least 21,6879 of 21
Rybelsusat least $2,424,524at least 1,6932 of 14
Wegovyat least $364,647at least 2445 of 20
Mounjaroat least $3,609,007at least 2,9231 of 25
ZepboundSuppressedSuppressed15 of 15
Liraglutide (generic name listing)at least $374,024at least 1,2138 of 21
VictozaSuppressedSuppressed2 of 2
Trulicityat least $2,991,673at least 2,6811 of 17
Bydureonat least $14,079at least 142 of 3
Exenatide (generic name listing)SuppressedSuppressed2 of 2
Soliquaat least $27,427at least 232 of 4

By quarter, 2025

Q1 2025at least $8,691,191at least 8,05011 of 34
Q2 2025at least $8,817,615at least 8,00311 of 35
Q3 2025at least $8,407,902at least 7,51715 of 37
Q4 2025at least $7,955,528at least 6,90812 of 38

By quarter, 2026 (posted so far)

Q1 2026at least $7,389,266at least 6,1099 of 35

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.